Compare · NEOG vs VNRX
NEOG vs VNRX
Side-by-side comparison of Neogen Corporation (NEOG) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NEOG and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.55B, about 551.2x VNRX ($4.6M).
- Over the past year, NEOG is up 107.6% and VNRX is down 97.5% - NEOG leads by 205.2 points.
- NEOG has been more active in the news (12 items in the past 4 weeks vs 9 for VNRX).
- NEOG has more recent analyst coverage (6 ratings vs 4 for VNRX).
- Company
- Neogen Corporation
- VolitionRX Limited
- Price
- $11.69+0.34%
- $0.33-12.95%
- Market cap
- $2.55B
- $4.6M
- 1M return
- +27.34%
- -61.29%
- 1Y return
- +107.64%
- -97.51%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 1989
- 2015
- News (4w)
- 12
- 9
- Recent ratings
- 6
- 4
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest NEOG
- Neogen upgraded by Piper Sandler with a new price target
- SEC Form DEFA14A filed by Neogen Corporation
- SEC Form DEF 14A filed by Neogen Corporation
- Chief Accounting Officer Moylan John Patrick covered exercise/tax liability with 2,365 units of Restricted Stock Units, decreasing direct ownership by 7% to 29,331 units (SEC Form 4)
- CEO Nassif Mikheal covered exercise/tax liability with 20,397 units of Restricted Stock Units, decreasing direct ownership by 44% to 25,655 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick was granted 8,584 units of Restricted Stock Units, increasing direct ownership by 36% to 32,155 units (SEC Form 4)
- Senior Vice President Ranalli Tamara A. was granted 25,751 shares (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 38,627 shares (SEC Form 4)
- CFO Riggsbee Richard Bryan was granted 51,502 shares (SEC Form 4)
- CEO Nassif Mikheal was granted 141,631 shares (SEC Form 4)
Latest VNRX
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- SEC Form S-8 filed by VolitionRX Limited
- SEC Form 10-Q filed by VolitionRX Limited
- VolitionRX Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
- Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
- VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
- Volition Advances Nu.Q® NETs Platform Towards Commercialization